EGFR and non-small cell lung carcinoma: Because M-COPA was effective to EGFR-TKI-naïve NCI-H1975 cells harboring an EGFR-T790M mutation, we next investigated whether M-COPA was also effective against NSCLC cells that had acquired resistance to first-generation EGFR-TKI.